Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
Total XVII
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- NCT03117751 ↗
- Active, not recruiting
- St. Jude Children's Research Hospital
- Focused
We haven't built an HCP commentary report on Total XVII yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Total XVII so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
- Interventions
- Prednisone; Vincristine; Daunorubicin; Pegaspargase; Erwinase®; Cyclophosphamide; Cytarabine; Mercaptopurine; Dasatinib; Methotrexate; Blinatumomab; Ruxolitinib; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Clofarabine; Vorinostat; Idarubicin; Nelarabine; Thioguanine; Asparaginase Erwinia chrysanthemi (recombinant)-rywn; Calaspargase Pegol
- Arms
- B-ALL and B-LLy, Low-risk · Experimental
- B-ALL and B-LLy, Standard-risk · Experimental
- B-ALL and B-LLy, High-risk · Experimental
- T-ALL and T-LLy, Standard-risk · Experimental
- T-ALL and T-LLy, High-risk · Experimental
- ALL, CEP72 T/T, Vincristine · Experimental
- ALL, CEP72 C/T or C/C, Vincristine · Experimental
- Enrollment
- 790
- Primary outcomes
- Event-free survival of ALL patients (EFS)
- Proportion of patients with CEP72TT genotype who develop two or more episodes of Grade 2 or higher neuropathy during Continuation
- Cumulative incidence of Grade 2 or higher neuropathy in patients with CEP72 CC or CT genotype
- Sponsor
- St. Jude Children's Research Hospital with Incyte Corporation, Amgen, Servier
- Start
- Mar 29, 2017
- Primary completion
- Sep 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03117751 · updated Jun 17, 2026
Publications
linked from the registry- Montanaro A, Monica G, Zamponi R, D'Antuono A, Andreani A, Andrei P, Su AH, Ciringione A, Sammarelli G, Todaro G, Rosati R, La Starza R, Mecucci C, Elia L, Gherli A, Vento F, Simoncini E, Lorusso B, Lagrasta CAM, Giaimo M, Pagliaro L, Marchesini M, Jimenez CR, Quaini F, Stegmaier K, Roti G. Inhibition of the atypical kinase WNK1 as a therapeutic strategy in TAL-related T-cell acute lymphoblastic leukemia. Blood. 2026 Sep 10;148(11):1423-1439. doi: 10.1182/blood.2025029901. PubMed 42154791